The main drug manufacturers in Romania registered profits of approximately 50m euros last year, compared with over 35m euros posted in 2005, according to ZF data. As a result, the biggest domestic producer, Terapia Ranbaxy, closed 2006 with net profit worth some 13.3m euros, the same as in 2005. The company’s turnover exceeded 70m euros. The company’s main shareholder, Indian group Ranbaxy, said it expected Romanian operations to be the main catalyst for profitability this year. The next company in terms of profit levels is LaborMed Pharma, the only Romanian-held player in the top 20 of the pharmaceutical industry. Antibiotice Iasi, which is due to be privatised this year, also maintains a high profitability rate, and ended 2006 with a 6.8m euro net income. In 2006, Zentiva Czech group posted a 6.5m-euro profit in Romania, while Biofarm logged net profit worth 3.6m euros. In H1, 2007, the domestic pharmaceuticals market increased by around 19% to 3.05bn RON (915m euros) and exceeded market players’ initial estimates.
ZF English
Producers derive profits of almost 50m euros on the pharmaceutical market
The main drug manufacturers in Romania registered profits of approximately 50m euros last year, compared with over 35m euros posted in 2005, according to ZF data. As a result, the biggest domestic producer, Terapia Ranbaxy, closed 2006 with net profit worth some 13